Detail akcie Sagimet Bioscn Rg-A online

Business Summary: Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sagimet Biosciences Inc revenues was not reported. Net loss increased 41% to $41.5M. Higher net loss reflects Developing and Commercializing therapeutics segment loss increase of 27% to $46.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.94 to -$1.28.